Synvista Therapeutics Competitors

Abliva AB (publ) (OTCMKTS:NEVPF) and Synvista Therapeutics (OTCMKTS:SYNI) are both medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their dividends, risk, valuation, earnings, analyst recommendations, institutional ownership and profitability.

Valuation and Earnings

This table compares Abliva AB (publ) and Synvista Therapeutics' top-line revenue, earnings per share and valuation.

Synvista Therapeutics has lower revenue, but higher earnings than Abliva AB (publ).

Analyst Recommendations

This is a breakdown of current ratings and recommmendations for Abliva AB (publ) and Synvista Therapeutics, as reported by MarketBeat.com.

Profitability

This table compares Abliva AB (publ) and Synvista Therapeutics' net margins, return on equity and return on assets.

Summary

Synvista Therapeutics beats Abliva AB (publ) on 2 of the 3 factors compared between the two stocks.

Achaogen (OTCMKTS:AKAOQ) and Synvista Therapeutics (OTCMKTS:SYNI) are both medical companies, but which is the better stock? We will contrast the two companies based on the strength of their dividends, earnings, analyst recommendations, profitability, institutional ownership, valuation and risk.

Valuation & Earnings

This table compares Achaogen and Synvista Therapeutics' gross revenue, earnings per share and valuation.

Synvista Therapeutics has lower revenue, but higher earnings than Achaogen.

Risk and Volatility

Achaogen has a beta of -0.81, suggesting that its share price is 181% less volatile than the S&P 500. Comparatively, Synvista Therapeutics has a beta of 10.26, suggesting that its share price is 926% more volatile than the S&P 500.

Analyst Ratings

This is a breakdown of current recommendations for Achaogen and Synvista Therapeutics, as reported by MarketBeat.

Profitability

This table compares Achaogen and Synvista Therapeutics' net margins, return on equity and return on assets.

Acusphere (OTCMKTS:ACUS) and Synvista Therapeutics (OTCMKTS:SYNI) are both medical companies, but which is the better stock? We will contrast the two companies based on the strength of their dividends, earnings, analyst recommendations, profitability, institutional ownership, valuation and risk.

Valuation & Earnings

This table compares Acusphere and Synvista Therapeutics' gross revenue, earnings per share and valuation.

Risk and Volatility

Acusphere has a beta of -0.29, suggesting that its share price is 129% less volatile than the S&P 500. Comparatively, Synvista Therapeutics has a beta of 10.26, suggesting that its share price is 926% more volatile than the S&P 500.

Analyst Ratings

This is a breakdown of current recommendations for Acusphere and Synvista Therapeutics, as reported by MarketBeat.

Profitability

This table compares Acusphere and Synvista Therapeutics' net margins, return on equity and return on assets.

Summary

Synvista Therapeutics beats Acusphere on 1 of the 1 factors compared between the two stocks.

ADiTx Therapeutics (NASDAQ:ADTX) and Synvista Therapeutics (OTCMKTS:SYNI) are both medical companies, but which is the better stock? We will contrast the two companies based on the strength of their dividends, earnings, analyst recommendations, profitability, institutional ownership, valuation and risk.

Valuation & Earnings

This table compares ADiTx Therapeutics and Synvista Therapeutics' gross revenue, earnings per share and valuation.

Analyst Ratings

This is a breakdown of current recommendations for ADiTx Therapeutics and Synvista Therapeutics, as reported by MarketBeat.

Profitability

This table compares ADiTx Therapeutics and Synvista Therapeutics' net margins, return on equity and return on assets.

Summary

ADiTx Therapeutics beats Synvista Therapeutics on 1 of the 1 factors compared between the two stocks.

Aeolus Pharmaceuticals (OTCMKTS:AOLS) and Synvista Therapeutics (OTCMKTS:SYNI) are both medical companies, but which is the better stock? We will contrast the two companies based on the strength of their dividends, earnings, analyst recommendations, profitability, institutional ownership, valuation and risk.

Analyst Ratings

This is a breakdown of current recommendations for Aeolus Pharmaceuticals and Synvista Therapeutics, as reported by MarketBeat.

Profitability

This table compares Aeolus Pharmaceuticals and Synvista Therapeutics' net margins, return on equity and return on assets.

Valuation & Earnings

This table compares Aeolus Pharmaceuticals and Synvista Therapeutics' gross revenue, earnings per share and valuation.

Risk and Volatility

Aeolus Pharmaceuticals has a beta of 2.36, suggesting that its share price is 136% more volatile than the S&P 500. Comparatively, Synvista Therapeutics has a beta of 10.26, suggesting that its share price is 926% more volatile than the S&P 500.

Summary

Synvista Therapeutics beats Aeolus Pharmaceuticals on 1 of the 1 factors compared between the two stocks.

Synvista Therapeutics (OTCMKTS:SYNI) and Affymax (OTCMKTS:AFFY) are both medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their valuation, dividends, profitability, risk, earnings, analyst recommendations and institutional ownership.

Analyst Recommendations

This is a breakdown of current recommendations and price targets for Synvista Therapeutics and Affymax, as reported by MarketBeat.com.

Profitability

This table compares Synvista Therapeutics and Affymax's net margins, return on equity and return on assets.

Valuation and Earnings

This table compares Synvista Therapeutics and Affymax's gross revenue, earnings per share (EPS) and valuation.

Risk & Volatility

Synvista Therapeutics has a beta of 10.26, suggesting that its share price is 926% more volatile than the S&P 500. Comparatively, Affymax has a beta of 2.83, suggesting that its share price is 183% more volatile than the S&P 500.

Summary

Synvista Therapeutics beats Affymax on 1 of the 1 factors compared between the two stocks.